A phase 2 trial of IO102-IO103 and nivolumab-relatlimab in previously untreated, unresectable melanoma
Publication/Presentation Date
5-2026
Volume
44
First Page
9519
Last Page
9519
Published In/Presented At
Disciplines
Medicine and Health Sciences
Department(s)
Hematology-Medical Oncology Division
Document Type
Article
COinS